Skip to search boxSkip to navigationSkip to main content

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

  • Diana O. Perkins(corresponding author)
    ,
  • Jacqueline L. Johnson
    ,
  • Robert M. Hamer
    ,
  • Robert B. Zipursky
    ,
  • Richard S. Keefe
    ,
  • Franca Centorrhino
*Corresponding author for this work
  • University of North Carolina at Chapel Hill
    ,
  • University of Toronto
    ,
  • Duke University
    ,
  • Harvard University
    ,
  • Stanford University
    ,
  • Utrecht University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Background: Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects. Method: In this 2-year prospective study of 254 patients recovering from a first episode of schizophrenia, schizophreniform, or schizoaffective disorder we examined the relationship between antipsychotic medication non-adherence and patient beliefs about: need for treatment, antipsychotic medication benefits, and negative aspects of antipsychotic medication treatment. We also examined the relationship between medication non-adherence and treatment with either haloperidol or olanzapine, and objective measures of symptom response and side effects. Results: The likelihood of becoming medication non-adherent for 1 week or longer was greater in subjects whose belief in need for treatment was less (HR = 1.75, 95% CI 1.16, 2.65, p = 0.0077) or who believed medications were of low benefit (HR = 2.88, 95 CI 1.79-4.65, p < 0.0001). Subjects randomized to haloperidol were more likely to become medication non-adherent for ≥ 1 week than subjects randomized to olanzapine (HR-1.51, 95% CI 1.01, 2.27, p = 0.045). Conclusion: Beliefs about need for treatment and the benefits of antipsychotic medication may be intervention targets to improve likelihood of long-term medication adherence in patients recovering from a first episode of schizophrenia, schizoaffective, or schizophreniform disorder.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 53-63 (11 pages)

Journal (Volume, Issue Number)

Schizophrenia Research (Volume 83, Issue 1)

Publication milestones

  • Published - 03/01/2006

Publication status

Published - 03/01/2006

ISSN

0920-9964

Publication IDs

  • Scopus: 33645329854
  • PubMed: 16529910

Publication metrics

Metrics

SciVal
FWCI
4.54
SciVal
Author count
26
SciVal
citations
128
SciVal
Paper percentile
96
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.03
Fractional count
36
Fractional count
0.97
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
144
Mentions
1
Captures
142

Funding Details

This work was supported by Lilly Research Laboratories and USPHS grants MH01905 (Dr. Perkins) MH00537, MH33127 (Dr. Lieberman), the UNC Mental Health and Neuroscience Clinical Research Center, the North Carolina Foundation of Hope, MH52376 and MH62157 (Dr. Green). This paper was based on results from the study of the Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis by the HGDH Study Group sponsored by Eli Lilly and Company.